Symbol | Exchange | Currency | ||
|---|---|---|---|---|
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| BATS Europe | GBP | Delayed | ||
| BATS Europe | SEK | Delayed | ||
| NASDAQ | USD | Real-time | ||
| OTC Markets | USD | Delayed | ||
| Mexico | MXN | Delayed | ||
| Stockholm | SEK | Real-time | ||
| Frankfurt | EUR | Delayed | ||
| TradeGate | EUR | Delayed | ||
| Xetra | EUR | Delayed | ||
| Frankfurt | EUR | Delayed | ||
| Buenos Aires | ARS | Delayed |
A combination of tremelimumab and AstraZeneca Plc's (NASDAQ: AZN) Imfinzi (durvalumab) extended the lives of newly diagnosed patients with unresectable hepatocellular carcinoma...
AstraZeneca says Imfinzi combo shows unprecedented liver-cancer survival rates
The combination of AstraZeneca Imfinzi (durvalumab) + the company experimental CTLA-4 inhibitor tremelimumab led to a clinically meaningful improvement in overall survival.
AstraZeneca Plc (AZN) is a leading global pharmaceutical company engaged in delivering life-changing medicines. The company produces and commercializes medicines for cancer,...
Drugmaker AstraZeneca (AZN) landed a bit of a prize recently. Its latest COVID-19 treatment now comes with authorization from the Food and Drug Administration. Said treatment also...
An analysis of phase 3 data on AstraZeneca and Daiichi Sankyo's Enhertu (am-trastuzumab deruxtecan-nxki) found it demonstrated a high progression-free survival and objective...
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company’s marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; Proteros biostructures GmbH to discover and develop novel small molecules. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; and Scorpion Therapeutics, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. The company was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 151.00 | 151.00 | 151.00 | +2.50 | +1.68% | 58.93K | London | |||
| 86.40 | 88.00 | 86.20 | -0.60 | -0.69% | 127.90K | London | |||
| 60.50 | 62.00 | 62.00 | +2.00 | +3.42% | 360.97K | London | |||
| 1,697.50 | 1,712.00 | 1,659.50 | +35.0 | +2.10% | 425.41K | London | |||
| 123.72 | 124.86 | 122.78 | +0.58 | +0.47% | 20.89M | London | |||
| 205.55 | 207.80 | 202.95 | -1.40 | -0.68% | 35.72M | London | |||
| 137.00 | 139.50 | 136.00 | +0.50 | +0.37% | 132.19K | London | |||
| 2,310.00 | 2,326.00 | 2,273.00 | +37.0 | +1.63% | 284.50K | London | |||
| 645.80 | 649.60 | 618.60 | +20.60 | +3.29% | 8.47M | London | |||
| 82.50 | 83.20 | 81.10 | +7.00 | +9.27% | 599.01K | London | |||
| 99.00 | 100.20 | 95.10 | +3.05 | +3.18% | 878.47K | London | |||
| 7,544.00 | 7,604.00 | 7,432.00 | +104.0 | +1.40% | 702.16K | London | |||
| 820.00 | 827.00 | 818.00 | -5.00 | -0.61% | 89.56K | London | |||
| 243.00 | 243.00 | 238.30 | +4.70 | +1.97% | 4.45M | London | |||
| 99.40 | 101.00 | 94.80 | +5.20 | +5.52% | 366.01K | London |